HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

Well-differentiated neuroendocrine tumor — Clinical Guidelines

Overview

Well-differentiated neuroendocrine tumors (NETs) are neoplasms arising from the neuroendocrine system, commonly found in the gastrointestinal tract, pancreas, and lungs. These tumors are characterized by their relatively indolent behavior but can exhibit variable aggressiveness depending on grade and location 1 4.

Diagnosis

Imaging: CT, MRI, and somatostatin receptor scintigraphy (SRS) are essential for localization and staging 1 22.

Biopsy and Histopathology: Definitive diagnosis often requires biopsy with histopathological examination, including assessment of Ki-67 proliferation index 25.

Ki-67 Index: Used for grading; values <2% typically indicate Grade 1, 2-20% Grade 2, and >20% Grade 3 7 17.

Fine-needle aspiration (FNA): Guided by endoscopic ultrasonography (EUS) can aid in diagnosis, especially in challenging cases 25.

Serotonin and other markers: Immunocytochemical studies for serotonin and other markers can support diagnosis in liver metastases 33.

Management

Surgical Resection: Primary treatment for localized disease, including metastatic sites when feasible, offering long-term survival benefits 12.

Radionuclide Therapy: Lutathera (177Lu-DOTATATE) is a key therapy for gastroenteropancreatic NETs, effective but with monitoring for adverse events 3 23.

Radiologic Interventions: Transarterial chemoembolization (TACE) and radioembolization with Y-90 for liver metastases 27 28.

Endoscopic Treatments: Endoscopic resection effective for small rectal NETs, with high complete resection rates 6.

Targeted Therapy: Emerging role for targeted agents like Entrectinib in specific molecular subtypes 18.

Supportive Care: Management of symptoms and comorbidities, including pain control and hormonal symptom management 2 29.

Special Populations

Elderly Patients: Management tailored to functional status and comorbidities; surgical options considered based on overall health 1 12.

Comorbidities: Careful consideration of comorbidities when selecting treatment modalities, particularly for interventions like radioembolization 16 28.

Key Recommendations

Surgical resection for localized and selected metastatic NETs improves survival outcomes (Evidence: Strong 1 12).

Use of Lutathera (177Lu-DOTATATE) for gastroenteropancreatic NETs with careful monitoring for adverse events (Evidence: Moderate 3).

Endoscopic resection is recommended for small, localized rectal NETs with high efficacy (Evidence: Moderate 6).

Consider radionuclide therapy for liver metastases, balancing efficacy and hepatotoxicity risks (Evidence: Moderate 23 28).

Tailor management to individual patient factors, especially in elderly patients and those with comorbidities (Evidence: Expert opinion).

References

1 Baudin E, Durand A, Buikhuisen W, Capdevila J, Caplin M, Deroose CM et al.. European Society of Neuroendocrine Tumors (ENETS) 2025 guidance paper for lung and thymic carcinoids. Journal of neuroendocrinology 2026. link 2 Panzuto F, Albertelli M, De Rimini ML, Rizzo FM, Grana CM, Cives M et al.. Radioligand therapy in the therapeutic strategy for patients with gastro-entero-pancreatic neuroendocrine tumors: a consensus statement from the Italian Association for Neuroendocrine Tumors (Itanet), Italian Association of Nuclear Medicine (AIMN), Italian Society of Endocrinology (SIE), Italian Association of Medical Oncology (AIOM). Journal of endocrinological investigation 2025. link 3 Chen H, Ma J. Post-marketing Safety Evaluation of Lutathera ( 177 Lu-DOTATATE) : A Pharmacovigilance Analysis of FDA Adverse Event Reporting System. Clinical nuclear medicine 2025. link 4 Lamarca A, Bartsch DK, Caplin M, Kos-Kudla B, Kjaer A, Partelli S et al.. European Neuroendocrine Tumor Society (ENETS) 2024 guidance paper for the management of well-differentiated small intestine neuroendocrine tumours. Journal of neuroendocrinology 2024. link 5 Osmani AH, Jaffery AH. Well-Differentiated Neuroendocrine of Left Kidney. Journal of the College of Physicians and Surgeons--Pakistan : JCPSP 2024. link 6 Varas Lorenzo M, Abad Belando R. Management and endoscopic treatment of rectal neuroendocrine tumors. Revista espanola de enfermedades digestivas 2023. link 7 Vesterinen T, Säilä J, Blom S, Pennanen M, Leijon H, Arola J. Automated assessment of Ki-67 proliferation index in neuroendocrine tumors by deep learning. APMIS : acta pathologica, microbiologica, et immunologica Scandinavica 2022. link 8 Chiloiro S, De Marinis L. From Pituitary Adenoma to Pituitary Neuroendocrine Tumors: How Molecular Pathways may Impact the Therapeutic Management?. Endocrine, metabolic & immune disorders drug targets 2021. link 9 Leyden S, Kolarova T, Bouvier C, Caplin M, Conroy S, Davies P et al.. Unmet needs in the international neuroendocrine tumor (NET) community: Assessment of major gaps from the perspective of patients, patient advocates and NET health care professionals. International journal of cancer 2020. link 10 Huang J, Zhang L. Frontiers in Genitourinary Pathology. Archives of pathology & laboratory medicine 2020. link 11 Akın Telli T, Esin E, Yalçın Ş. Clinicopathologic Features of Gastroenteropancreatic Neuroendocrine Tumors: A Single-center Experience. Balkan medical journal 2020. link 12 Chakedis J, Beal EW, Lopez-Aguiar AG, Poultsides G, Makris E, Rocha FG et al.. Surgery Provides Long-Term Survival in Patients with Metastatic Neuroendocrine Tumors Undergoing Resection for Non-Hormonal Symptoms. Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract 2019. link 13 Lim KHJ, Valle JW, Lamarca A. Unusual skull base metastasis from neuroendocrine tumor: a case report. Journal of medical case reports 2019. link 14 Hallet J, Davis LE, Mahar AL, Isenberg-Grzeda E, Bubis LD, Myrehaug S et al.. Symptom Burden at the End of Life for Neuroendocrine Tumors: An Analysis of 2579 Prospectively Collected Patient-Reported Outcomes. Annals of surgical oncology 2019. link 15 Fazio N, Milione M. Gastroenteropancreatic Neuroendocrine Carcinomas: The NET G3 Subcategory Is a Reality. The oncologist 2017. link 16 Su YK, Mackey RV, Riaz A, Gates VL, Benson AB, Miller FH et al.. Long-Term Hepatotoxicity of Yttrium-90 Radioembolization as Treatment of Metastatic Neuroendocrine Tumor to the Liver. Journal of vascular and interventional radiology : JVIR 2017. link 17 Grillo F, Valle L, Ferone D, Albertelli M, Brisigotti MP, Cittadini G et al.. KI-67 heterogeneity in well differentiated gastro-entero-pancreatic neuroendocrine tumors: when is biopsy reliable for grade assessment?. Endocrine 2017. link 18 Sigal D, Tartar M, Xavier M, Bao F, Foley P, Luo D et al.. Activity of Entrectinib in a Patient With the First Reported . Journal of the National Comprehensive Cancer Network : JNCCN 2017. link 19 Papadakis GZ, Millo C, Bagci U, Sadowski SM, Stratakis CA. Schmorl Nodes Can Cause Increased 68Ga DOTATATE Activity on PET/CT, Mimicking Metastasis in Patients With Neuroendocrine Malignancy. Clinical nuclear medicine 2016. link 20 Bouma G, van Faassen M, Kats-Ugurlu G, de Vries EG, Kema IP, Walenkamp AM. Niacin (Vitamin B3) Supplementation in Patients with Serotonin-Producing Neuroendocrine Tumor. Neuroendocrinology 2016. link 21 Caplin ME, Baudin E, Ferolla P, Filosso P, Garcia-Yuste M, Lim E et al.. Pulmonary neuroendocrine (carcinoid) tumors: European Neuroendocrine Tumor Society expert consensus and recommendations for best practice for typical and atypical pulmonary carcinoids. Annals of oncology : official journal of the European Society for Medical Oncology 2015. link 22 Orgera G, Krokidis M, Cappucci M, Gourtsoyianni S, Tipaldi MA, Hatzidakis A et al.. Current status of Interventional Radiology in the management of Gastro-Entero-Pancreatic Neuroendocrine Tumours (GEP-NETs). Cardiovascular and interventional radiology 2015. link 23 de Baere T, Deschamps F, Tselikas L, Ducreux M, Planchard D, Pearson E et al.. GEP-NETS update: Interventional radiology: role in the treatment of liver metastases from GEP-NETs. European journal of endocrinology 2015. link 24 Lindholm EB, Gupta MK, Boudreaux JP, Burns LA, Wang YZ, Woltering EA. The incidence of over-the-counter medication use in patients with midgut neuroendocrine tumors. The American surgeon 2015. link 25 Gornals J, Varas M, Catalá I, Maisterra S, Pons C, Bargalló D et al.. Definitive diagnosis of neuroendocrine tumors using fine-needle aspiration-puncture guided by endoscopic ultrasonography. Revista espanola de enfermedades digestivas 2011. link 26 Williamson JM, Thorn CC, Spalding D, Williamson RC. Pancreatic and peripancreatic somatostatinomas. Annals of the Royal College of Surgeons of England 2011. link 27 Kvols LK, Turaga KK, Strosberg J, Choi J. Role of interventional radiology in the treatment of patients with neuroendocrine metastases in the liver. Journal of the National Comprehensive Cancer Network : JNCCN 2009. link 28 Madoff DC, Gupta S, Ahrar K, Murthy R, Yao JC. Update on the management of neuroendocrine hepatic metastases. Journal of vascular and interventional radiology : JVIR 2006. link 29 Shah SA, Mery CM, Zinner MJ. Small bowel varices from neuroendocrine tumor of the pancreas. Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract 2005. link 30 Gillams A, Cassoni A, Conway G, Lees W. Radiofrequency ablation of neuroendocrine liver metastases: the Middlesex experience. Abdominal imaging 2005. link 31 Freschi M, Colombo R, Naspro R, Rigatti P. Primary and pure neuroendocrine tumor of the prostate. European urology 2004. link 32 Brown KT, Koh BY, Brody LA, Getrajdman GI, Susman J, Fong Y et al.. Particle embolization of hepatic neuroendocrine metastases for control of pain and hormonal symptoms. Journal of vascular and interventional radiology : JVIR 1999. link70055-2) 33 Wilander E. Serotonin in cytologic samples of liver metastases of carcinoid tumors. An immunocytochemical study with a monoclonal antibody. Acta cytologica 1985. link 34 Bostwick DG, Roth KA, Barchas JD, Bensch KG. Gastrin-releasing peptide immunoreactivity in intestinal carcinoids. American journal of clinical pathology 1984. link

Well-differentiated neuroendocrine tumor